OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chaudhary on Remaining Challenges With CAR T-Cell Therapy

January 25th 2017

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses challenges that oncologists continue to face when treating patients with CAR T-cell therapy.

Dr. Philip on Drug Developments for Pancreatic Cancer

January 25th 2017

Philip A. Philip, MD, PhD, FRCP, professor of Medicine at Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses drug developments for patients with pancreatic cancer.

Dr. Chang on Genomic Testing in Breast Cancer

January 25th 2017

Jenny C. Chang, MD, director of the Methodist Cancer Center at Houston Methodist Hospital, discusses genomic testing in breast cancer.

Dr. Catton on Omitting Radiation Therapy in Sarcoma

January 25th 2017

Charles Catton, MD, professor, Department of Radiation Oncology, University of Toronto, discusses the notion of omitting radiation therapy in the treatment of patients with extremity sarcoma.

Dr. Strosberg on Quality of Life for Midgut Neuroendocrine Tumors

January 25th 2017

Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses quality of life in patients with midgut neuroendocrine tumors (NETs).

Dr. Stein on AR-Resistance in Prostate Cancer

January 25th 2017

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses androgen receptor–resistance in prostate cancer.

Dr. Loaiza-Bonilla on Right- Versus Left-Sided Colorectal Cancer

January 24th 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, specialized in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses findings of patients with right- versus left-sided tumors of colorectal cancer (CRC).

Dr. Pal on Preoperative Immunotherapy in Patients With RCC

January 24th 2017

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the potential with immunotherapy in the preoperative setting for patients with renal cell carcinoma.

Dr. Tereffe on Treatment After Neoadjuvant Chemotherapy in Breast Cancer

January 24th 2017

Welela Tereffe, MD, associate professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the role of radiation therapy in the treatment of patients with breast cancer who previously received neoadjuvant chemotherapy.

Dr. Leis on Promising Combo Regimens Being Explored in CLL

January 24th 2017

Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses combination regimens that seem promising and are under investigation in the treatment landscape of chronic lymphocytic leukemia.

Dr. Strosberg on Future of 177Lu-Dotatate Therapy in Neuroendocrine Tumors

January 24th 2017

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the future of using 177Lu-dotatate therapy to treat patients with neuroendocrine tumors.

Dr. Terashima on Bursectomy for Subserosal and Serosal Gastric Cancer

January 24th 2017

Masanori Terashima, MD, PhD, FACS, chairman of the Japanese Clinical Oncology Group, discusses bursectomy for patients with subserosal and serosal gastric cancer.

Dr. Seiwert on Next Steps in Treatment of Patients With Head and Neck Cancer

January 24th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the next steps researchers are taking to improve survival outcomes for patients with head and neck cancer.

Dr. Ku on Combinations and Sequencing of Treatments for Gastric Cancer

January 24th 2017

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations of treatments for patients with gastric and esophageal cancers.

Dr. Royce Reflects on Advances in HER2+ Breast Cancer

January 24th 2017

Melanie E. Royce, MD, PhD, co-director, Protocol Review and Monitoring System, member, Women’s Cancers Research Program, associate professor of Medicine, University of New Mexico Comprehensive Cancer Center, discusses some of the advancements in the field of HER2-positive breast cancer.

Dr. Kumar on the Safety and Efficacy of Venetoclax in Myeloma

January 24th 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the safety profile and the survival benefits associated with venetoclax in the treatment of patients with multiple myeloma.

Dr. Figlin on TKI Therapy Options in Renal Cell Carcinoma

January 23rd 2017

Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses tyrosine kinase inhibitors that he uses to treat patients with renal cell carcinoma.

Dr. Muro on Results of PaFF-K Study in Colorectal Cancer

January 23rd 2017

Kei Muro, MD, Aichi Cancer Center Hospital, discusses the results of the PaFF-K study in metastatic colorectal cancer.

Dr. Harris on Controversy of PSA Testing for Prostate Cancer

January 21st 2017

Richard Harris, MD, urologist, UroPartners, discusses PSA testing for patients with prostate cancer and the controversial grade D recommendation of the United States Task Force.

Dr. May on Olaratumab Activity in Pediatric Bone and Soft Tissue Sarcoma

January 21st 2017

Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.